TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29084725

Group type: EXPERIMENTAL
Intervention: Daily clinical measures including strength, palpation, flexibility, and functional tests
Number of subjects: 131
Study: 28976863

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based chemotherapy
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Rituximab-based chemotherapy
Number of subjects: 1202
Study: 26250487

Group type: EXPERIMENTAL
Intervention: Nutritional counseling (NC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144
Study: 23829882

Group type: EXPERIMENTAL
Intervention: Manual therapy (thrust or nonthrust manipulation) with a standardized exercise program for 2 treatment sessions
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Manual therapy (thrust or nonthrust manipulation)
Number of subjects: 149
Study: 21930465

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent
Number of subjects: 461

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 461
Study: 18345342

Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching exercise (2 times daily for 3 weeks) with subtalar joint in supination or pronation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (contralateral lower extremity)
Number of subjects: 33
Study: 17151364

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Interferon alfa plus cytarabine
Number of subjects: 1106
Study: 12728166

Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous nasal spray (50 micro g) into each nostril twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 50
Study: 10825306

Group type: EXPERIMENTAL
Intervention: remifentanil-propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: alfentanil-propofol
Number of subjects: 30
Study: 8864314

Group type: EXPERIMENTAL
Intervention: BAY x 7195 aerosol 2 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: BAY x 7195 aerosol 4 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1687425

Group type: EXPERIMENTAL
Intervention: pindolol 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: propranolol 80 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: not specified
Number of subjects: 30
Study: 6135830

Group type: EXPERIMENTAL
Intervention: 0.1 ml HDCSV intradermally at each of eight sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (im) administration of HDCSV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-site id regimen with booster on day 91
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine given subcutaneously (sc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semple vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human rabies-immune globulin (HRIG) at 40 IU per kg
Number of subjects: 0
Study: 3755650

Group type: EXPERIMENTAL
Intervention: piperazinedione at a dose of 9 mg/m2 iv every 3 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: cisplatin
Number of subjects: 42
Study: 29510351

Group type: EXPERIMENTAL
Intervention: Long-exposure group (LE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short-exposure group (SE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 60
Study: 27542791

Group type: EXPERIMENTAL
Intervention: First-generation balloon-expandable transcatheter heart valve (SAPIEN THV)
Number of subjects: 410
Study: 24401928

Group type: EXPERIMENTAL
Intervention: NPLD (50 mg/m² every 3 weeks for six cycles) + trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly) + paclitaxel (80 mg/m² weekly)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Trastuzumab + paclitaxel (same doses as above)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: NPLD + trastuzumab + paclitaxel
Number of subjects: 364

Group type: COMPARATOR
Intervention: Trastuzumab + paclitaxel
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: NPLD + trastuzumab + paclitaxel in ER- and PR-negative tumors
Number of subjects: 364

Group type: COMPARATOR
Intervention: Trastuzumab + paclitaxel in ER- and PR-negative tumors
Number of subjects: 364
Study: 22245700

Group type: EXPERIMENTAL
Intervention: Child-focused intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-focused intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 0
Study: 20060191

Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18768414

Group type: EXPERIMENTAL
Intervention: 24-week home-based program of physical activity
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Word list delayed recall
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating sum of boxes
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Word list total immediate recall
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Digit symbol coding
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Verbal fluency
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Beck depression score
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Medical Outcomes 36-Item Short-Form physical and mental component summaries
Number of subjects: 170
Study: 15486001

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 84
Study: 14676103

Group type: EXPERIMENTAL
Intervention: Intravenous mesna regimen (20% ifosfamide dose) at 0, 4, and 8 h
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous/oral mesna regimen (i.v. mesna at 0 h, oral tablet at 2 and 6 h)
Number of subjects: 17
Study: 10560956

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (matched for age and gender)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 7781792

Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) supplementation for 15 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) supplementation for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cessation of EFA intake for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (advanced colorectal cancer without EFA supplementation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) supplementation
Number of subjects: 30
Study: 2031511

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg q.i.d.)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg q.i.d.)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (two tablets q.i.d.)
Number of subjects: 120
Study: 7183131

Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study: 30923082

Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 50
Study: 29677580

Group type: EXPERIMENTAL
Intervention: Skill demonstration video delivered by smartphone
Number of subjects: 87

Group type: COMPARATOR
Intervention: Regular nursing skills lab demonstration (comparison group)
Number of subjects: 87
Study: 27454266

Group type: EXPERIMENTAL
Intervention: TP injections using particulate steroids mixed with a local anesthetic
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline alone (control)
Number of subjects: 43
Study: 24519657

Group type: EXPERIMENTAL
Intervention: Fourier decomposition (FD) method for quantifying ventilation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Previously published methods for quantitative ventilation assessment
Number of subjects: 20
Study: 22328340

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: No medication (ADHD without MPH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 20218999

Group type: EXPERIMENTAL
Intervention: Mifepristone priming followed by misoprostol
Number of subjects: 388

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 388
Study: 17462517

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16385874

Group type: EXPERIMENTAL
Intervention: CCR5 antagonists (experimental medications)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enfuvirtide (previously approved medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other mechanisms of action (attachment inhibitors, CXCR4 inhibitors)
Number of subjects: 0
Study: 11285326

Group type: EXPERIMENTAL
Intervention: High genistein intake
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Genistein, daidzein, and total isoflavone intake
Number of subjects: 208
Study: 9368870

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: No colonoscopy screening (Control)
Number of subjects: 0
Study: 8253244

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 2892336

Group type: EXPERIMENTAL
Intervention: SMS 201‐995
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 plus injection sclerotherapy
Number of subjects: 9
Study: 31431112

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay with sex-specific thresholds (>16 ng/L women, >34 ng/L men)
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I and sex-specific thresholds
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Typical symptoms
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Typical features presence
Number of subjects: 1941
Study: 28390493

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral conjoint therapy (CBCT) for PTSD
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 36
Study: 25419681

Group type: EXPERIMENTAL
Intervention: Supplementary feeding for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (treated until WHZ > -2)
Number of subjects: 0
Study: 24308728

Group type: EXPERIMENTAL
Intervention: Spirometry test and information regarding the test for smoking cessation after 1 year.
Number of subjects: 444

Group type: COMPARATOR
Intervention: Brief anti-smoking intervention (for both groups).
Number of subjects: 444
Study: 21451393

Group type: EXPERIMENTAL
Intervention: Total fundoplication (I)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Toupet posterior partial fundoplication (II)
Number of subjects: 137
Study: 19301132

Group type: EXPERIMENTAL
Intervention: NICO monitor with ver. 4.2 software
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NICO monitor with ver. 5.0 software
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous cardiac output (CCO)
Number of subjects: 42
Study: 16719652

Group type: EXPERIMENTAL
Intervention: Tradeoff size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediating effect of sacrifice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediating effect of argumentation
Number of subjects: 0
Study: 15771223

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 4656

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 4656
Study: 11775730

Group type: EXPERIMENTAL
Intervention: Antecolic, isoperistaltic gastrojejunostomy, jejunojejunostomy, and hepaticojejunostomy after cholecystectomy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hepaticojejunostomy and antecolic, antiperistaltic gastrojejunostomy after cholecystectomy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 44
Study: 9257362

Group type: EXPERIMENTAL
Intervention: Fenoterol/ipratropium bromide HFA134a inhaler (100 micrograms fenoterol/40 micrograms ipratropium bromide)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Conventional CFC inhaler (Berodual) (100 micrograms fenoterol/40 micrograms ipratropium bromide)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8275618

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 12
Study: 17165348

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.02 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal saline (ITS)
Number of subjects: 40
Study: 29683914

Group type: EXPERIMENTAL
Intervention: Non-periodized (NP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Traditional periodization (TP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (UP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 33
Study: 26652763

Group type: EXPERIMENTAL
Intervention: MCFA-rich diet for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: LCFA-rich diet for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MCFA-rich diet
Number of subjects: 16
Study: 26301875

Group type: EXPERIMENTAL
Intervention: Real 20 Hz rTMS applied to the left primary motor cortex (M1) for 5 consecutive days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham 20 Hz rTMS applied to the left primary motor cortex (M1) for 5 consecutive days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EEG changes
Number of subjects: 11
Study: 23378150

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Stent oversizing
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Lipid rich plaque at proximal edge
Number of subjects: 206

Group type: COMPARATOR
Intervention: Male gender
Number of subjects: 206
Study: 21636319

Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment guided by EMG
Number of subjects: 26

Group type: COMPARATOR
Intervention: Botulinum toxin treatment based on clinical judgement alone
Number of subjects: 26
Study: 18438209

Group type: EXPERIMENTAL
Intervention: Learning group (LG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 12
Study: 17062965

Group type: EXPERIMENTAL
Intervention: 0.02 microg x kg(‐1) x min(‐1) of hANP
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (non-hANP)
Number of subjects: 150
Study: 12746037

Group type: EXPERIMENTAL
Intervention: Explicit gateway message ads
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Implicit gateway message ads
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 418
Study: 10984710

Group type: EXPERIMENTAL
Intervention: Silver-coated screws
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uncoated stainless steel screws
Number of subjects: 24
Study: 7992901

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous lidocaine (0.4 mg.kg-1 bolus followed by 30 micrograms.kg-1.min-1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine (3-4 micrograms.kg-1 oral)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal lidocaine (2 ml of 4% spray)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 40
Study: 2608700

Group type: EXPERIMENTAL
Intervention: 3 mg pessary
Number of subjects: 83

Group type: COMPARATOR
Intervention: 1700 micrograms film
Number of subjects: 83
Study: 4219401

Group type: EXPERIMENTAL
Intervention: 1.5% amino acid solution with 10% carbohydrates (sorbitol, xylitol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional basic electrolyte solution
Number of subjects: 40
Study: 31575306

Group type: EXPERIMENTAL
Intervention: Maximum noise reduction (NR) setting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum directional setting (broadband directionality)
Number of subjects: 20
Study: 30896603

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (4 cycles of 5‐minute right upper limb ischemia and 5‐minute reperfusion)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham preconditioning (4 cycles of 5‐minute right upper limb pseudo ischemia and 5‐minute reperfusion)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham preconditioning
Number of subjects: 130
Study: 28100130

Group type: EXPERIMENTAL
Intervention: Cold water immersion (8°C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cool water immersion (22°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (rested in a seated position)
Number of subjects: 12
Study: 26074331

Group type: EXPERIMENTAL
Intervention: Maximum inspiratory pressure (MIP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maximum expiratory pressure (MEP)
Number of subjects: 40
Study: 24127346

Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept 2 mg/kg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept 4 mg/kg
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Intravenous aflibercept
Number of subjects: 215
Study: 22516856

Group type: EXPERIMENTAL
Intervention: Custom foot orthoses (CFO)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sham orthoses (Control)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Healthy participants (normal foot alignment)
Number of subjects: 154
Study: 19406402

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg/day
Number of subjects: 20
Study: 18090158

Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding with fiber
Number of subjects: 148

Group type: COMPARATOR
Intervention: Intermittent enteral feeding with fiber
Number of subjects: 148

Group type: COMPARATOR
Intervention: Intermittent enteral feeding without fiber
Number of subjects: 148

Group type: COMPARATOR
Intervention: Continuous enteral feeding without fiber
Number of subjects: 148
Study: 15573736

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride at 1-2 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11489008

Group type: EXPERIMENTAL
Intervention: Ovarian Cancer Trials Intergroup Network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gynecologic Cancer Intergroup (GCIG)
Number of subjects: 0
Study: 9849445

Group type: EXPERIMENTAL
Intervention: Erythropoietin (200 U/kg body weight daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 7723344

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 26
Study: 2048592

Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl estradiol and 1.0 mg norethindrone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol and 1.0 mg norethindrone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol and 0.5 mg norethindrone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Type O women using the highest estrogen dose preparation (50 micrograms)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Non-type O women using the lowest progestin dose preparation (0.5 mg)
Number of subjects: 192
Study: 7031981

Group type: EXPERIMENTAL
Intervention: Cod liver oil (CLO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Corn oil (CO)
Number of subjects: 10
Study: 31300325

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) robotic simulation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Robotic dry-laboratory simulation training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Robotic suturing quality
Number of subjects: 58
Study: 31144265

Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (exercise arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women farther out from surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 28120446

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 204
Study: 25212456

Group type: EXPERIMENTAL
Intervention: Deferasirox treatment for iron overload
Number of subjects: 0
Study: 23689577

Group type: EXPERIMENTAL
Intervention: Tacrolimus combined with corticosteroids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) combined with corticosteroids
Number of subjects: 100
Study: 22164271

Group type: EXPERIMENTAL
Intervention: 0.4 ng/kg LPS
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.8 ng/kg LPS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18853166

Group type: EXPERIMENTAL
Intervention: Serum antioxidants (glutathione and catalase)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Serum nitric oxide (NO)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 37
Study: 17244850

Group type: EXPERIMENTAL
Intervention: Behavioral intervention program
Number of subjects: 194

Group type: COMPARATOR
Intervention: Reference group (age- and sex-matched healthy individuals)
Number of subjects: 194
Study: 15531491

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Regular follow-up (Control)
Number of subjects: 53
Study: 12092634

Group type: EXPERIMENTAL
Intervention: Combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9632125

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine for 3 months followed by clinic visits
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 132

Group type: COMPARATOR
Intervention: Clinic visits
Number of subjects: 132

Group type: COMPARATOR
Intervention: Behavioural group therapy
Number of subjects: 132
Study: 8291731

Group type: EXPERIMENTAL
Intervention: 60 mg intravenous (2 ml) ketorolac, followed by 30 mg intravenously (in saline 20 ml) over 30 min every 6 h
Number of subjects: 198

Group type: COMPARATOR
Intervention: 2 ml intravenous saline, followed by saline 20 ml intravenously over 30 min every 6 h
Number of subjects: 198